1y return+187.5%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2024: $216 against $127 in the S&P 500.2
Foresite Capital Management VI LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| CGONCG Oncology, Inc. | $168.4M | 26.2% | +6.7% |
| ALMSAlumis Inc. | $119.5M | 18.6% | |
| SPTXSeaport Therapeutics, Inc. | $38.7M | 6.0% | New |
| DNLIDenali Therapeutics Inc. | $35.9M | 5.6% | +15.4% |
| CLDXCelldex Therapeutics, Inc. | $32.7M | 5.1% | +178.5% |
| AGIOAgios Pharmaceuticals, Inc. | $29.1M | 4.5% | +49.5% |
| CRVSCorvus Pharmaceuticals, Inc. | $27.4M | 4.3% | |
| PBLSParabilis Medicines, Inc. | $27.3M | 4.3% | New |
| GH Research PLCCUSIP G3855L106 | $25.3M | 3.9% | +198.1% |
| JBIOJade Biosciences, Inc. | $19.7M | 3.1% | +177.1% |
| HNGEHinge Health, Inc. | $18.3M | 2.8% | |
| KYMRKymera Therapeutics, Inc. | $16.8M | 2.6% | |
| AtaiBeckley Inc.CUSIP 04650F101 | $14.5M | 2.3% | |
| VSTMVerastem, Inc. | $12.0M | 1.9% | |
| BEAMBeam Therapeutics Inc. | $11.3M | 1.8% | New |
| NERVMinerva Neurosciences, Inc. | $11.0M | 1.7% | |
| AVBPArriVent BioPharma, Inc. | $10.5M | 1.6% | New |
| AURAAura Biosciences, Inc. | $9.5M | 1.5% | New |
| Crinetics Pharmaceuticals, Inc.CUSIP 22663K107 | $7.9M | 1.2% | |
| Research Alliance Corp IIICUSIP G75226103 | $3.2M | 0.5% | New |
| Zura Bio LtdCUSIP G9TY5A101 | $2.7M | 0.4% | |
| KLRAKailera Therapeutics, Inc. | $826K | 0.1% | New |
| IRONDisc Medicine, Inc. | $71K | 0.0% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ALMSAlumis Inc. | December 31, 2024 | +258.0% | $119.5M |
| KYMRKymera Therapeutics, Inc. | December 31, 2024 | +185.0% | $16.8M |
| CRVSCorvus Pharmaceuticals, Inc. | December 31, 2024 | +179.3% | $27.4M |
| CGONCG Oncology, Inc. | December 31, 2024 | +147.7% | $168.4M |
| GH Research PLCCUSIP G3855L106 | March 31, 2026 | +91.2% | $25.3M |
| DNLIDenali Therapeutics Inc. | September 30, 2025 | +77.1% | $35.9M |
| HNGEHinge Health, Inc. | June 30, 2025 | +60.4% | $18.3M |
| JBIOJade Biosciences, Inc. | March 31, 2026 | +58.1% | $19.7M |
| AtaiBeckley Inc.CUSIP 04650F101 | March 31, 2026 | +48.9% | $14.5M |
| AGIOAgios Pharmaceuticals, Inc. | December 31, 2025 | +36.3% | $29.1M |
Sold off last quarter
- Centessa Pharmaceuticals plcCUSIP 152309100 was $54.2M
- OKUROnKure Therapeutics, Inc. was $6.0M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +16.3% | +14.8% |
| March 31, 2026 | +48.5% | −4.6% |
| December 31, 2025 | +15.0% | +2.4% |
| September 30, 2025 | +44.8% | +7.8% |
| June 30, 2025 | −7.6% | +10.5% |
| March 31, 2025 | −18.7% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Foresite Capital Management VI LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2013341&type=13F-HR&dateb=&owner=include&count=40CIK 2013341
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2013341/000110465926097133/Filed August 14, 2026 · accession 0001104659-26-097133